Related references
Note: Only part of the references are listed.A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus
Feroze Ganaie et al.
MBIO (2020)
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015
Jason LeBlanc et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)
Jason J. LeBlanc et al.
VACCINE (2019)
The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017
Shinthuja Wijayasri et al.
PLOS ONE (2019)
Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15
Heather J. Adam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Streptococcus pneumoniae: transmission, colonization and invasion
Jeffrey N. Weiser et al.
NATURE REVIEWS MICROBIOLOGY (2018)
Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects
Keith P. Klugman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
Michele Wilson et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children
Samuel Sigurdsson et al.
VACCINE (2017)
Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations (Publication with Expression of Concern. See vol. 68, pg. 534, 2019)
Pontus Naucler et al.
CLINICAL INFECTIOUS DISEASES (2017)
Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive Streptococcus pneumoniae isolates after implementation of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Bulgaria
Lena Setchanova et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2017)
Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine
Sara Tomczyk et al.
CLINICAL INFECTIOUS DISEASES (2016)
Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014
C. Sheppard et al.
EUROSURVEILLANCE (2016)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Pauline A. Waight et al.
LANCET INFECTIOUS DISEASES (2015)
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
Matthew R. Moore et al.
LANCET INFECTIOUS DISEASES (2015)
Choosing between 7-, 10-and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014)
David Bin-Chia Wu et al.
VACCINE (2015)
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
Nick J. Andrews et al.
LANCET INFECTIOUS DISEASES (2014)
Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012
Walter H. B. Demczuk et al.
CANADIAN JOURNAL OF MICROBIOLOGY (2013)
Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation
Silvia R. dos Santos et al.
VACCINE (2013)
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
Anneke Steens et al.
VACCINE (2013)
Cost-effectiveness of 2+1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Stephanie R. Earnshaw et al.
BMC INFECTIOUS DISEASES (2012)
Prevention of Antibiotic-Nonsusceptible Streptococcus pneumoniae With Conjugate Vaccines
Lee M. Hampton et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
William P. Hausdorff et al.
BMC PEDIATRICS (2010)
Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines
Anderson W. Chuck et al.
VACCINE (2010)
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007
Julie A. Bettinger et al.
VACCINE (2010)
Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention
Joseph P. Lynch et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006
Gregory J. Tyrrell et al.
VACCINE (2009)
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the united states during the era of widespread PCV7 vaccination, 1998-2004
Lauri A. Hicks et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae
MH Kyaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Streptococcus pneumoniae: Description of the pathogen, disease epidemiology, treatment, and prevention
AE Bridy-Pappas et al.
PHARMACOTHERAPY (2005)
Share Paper
